# Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer

> **NCT03276013** · PHASE2 · COMPLETED · sponsor: **Vall d'Hebron Institute of Oncology** · enrollment: 48 (actual)

## Conditions studied

- Endometrial Neoplasms

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03276013
- **Lead sponsor:** Vall d'Hebron Institute of Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-30
- **Primary completion:** 2020-04-30
- **Final completion:** 2021-08-26
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2021-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03276013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03276013, "Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03276013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*